Contact this trialFirst, we need to learn more about you.
GMCI + Immunotherapy for Lung Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is testing whether adding a new cancer treatment, Gene Mediated Cytotoxic Immunotherapy (GMCI™), to the standard of care improves response rates and clinical outcomes for patients with stage III/IV non-small cell lung cancer who have stopped responding to their first line of immune checkpoint inhibitor (ICI) treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service